Milestone Scientific, Inc.
(NYSE: MLSS) is a leading medical research and development company that designs
and patents innovative injection technology. Since 1995, the company’s
commitment to advancing the science of computer-controlled drug delivery technologies
has helped it earn global distinction as an industry leader in the fields of
medicine and dentistry. Milestone’s patented CompuFlo® system and DPS Dynamic
Pressure Sensing® technology are revolutionary tools that enable practitioners
to accomplish a collection of tasks that exceed the capabilities of the 150
year-old manual syringe.
The CompuFlo® system provides a
safer, painless delivery alternative for all types of subcutaneous injections
in the medical practice. Utilizing Milestone’s proprietary pressure sensing
technology, the system offers safe, effective feedback to assist healthcare
providers in identifying a specific anatomic location. In addition to more
accurate injections, the platform is capable of documenting injection events to
provide more reliable recordkeeping for both patients and healthcare providers.
In recent months, Milestone,
through its Epidural & IA subsidiary, has turned its attention towards a
clinical trial to verify the placement of the epidural needle tip in the lumbar
epidural space. Since receiving FDA approval in March, the company has opened
enrollment for clinical testing, aiming to enroll up to 400 patients in the
trial at four sites throughout the United States.
“A major focus of the company in
2015 is commercializing the first medical applications of our technology
platform, including those licensed by our Epidural & IA Subsidiary,” stated
Leonard Osser, chief executive officer of Milestone. “Our Epidural & IA
Subsidiary has been in negotiations with distributors in a number of countries…
[and] recently signed its first distribution agreement with TRIMED SP.z.o.o.,
one of the largest distributors of diagnostic equipment in Poland.”
In the first quarter of 2015,
Milestone made took major steps towards realizing sustainable growth by signing
a letter of intent with MILA International for marketing, distribution and
commercialization of an anesthetic delivery instrument for maxillary nerve
block procedures in horses. Through this agreement, the company will gain access
to the $24 billion global animal health industry, providing an additional
platform for continued expansion.
“Our strategy is to collaborate
on the development, commercialization and distribution of an anesthetic
delivery instrument… [for which] MILA will be responsible for marketing and
distribution and Milestone will manufacture product,” continued Osser.
For prospective investors, the
company’s continued dedication to innovation and an increasingly broad
collection of target markets provide the opportunity to realize sustainable
returns in the future.
For more information, visit
www.milesci.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
